JME Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Molecular Endocrinology (2006) 37 71-80    DOI: 10.1677/jme.1.02082
© 2006 Society for Endocrinology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casal, A. J
Right arrow Articles by Ferrari, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casal, A. J
Right arrow Articles by Ferrari, P.

A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity

Andres J Casal, Victoria J P Sinclair1, Alessandro M Capponi, Jérôme Nicod1, Uyen Huynh-Do1 and Paolo Ferrari1,2

Division of Endocrinology, Diabetology & Nutrition, University Hospital, Geneva 1211, Switzerland
1 Division of Nephrology, Inselspital, Berne 3010, Switzerland
2 Department of Nephrology, Fremantle Hospital, University of Western Australia, Perth 6160, Australia

(Requests for offprints should be addressed to P Ferrari; Email: paolo.ferrari{at}health.wa.gov.au)

We have identified a novel cytosine/thymidine polymorphism of the human steroidogenic acute regulatory (StAR) gene promoter located 3 bp downstream of the steroidogenic factor-1 (SF-1)-binding site and 9 bp upstream of the TATA box (ATTTAAG). Carriers of this mutation have a high prevalence of primary aldosteronism. In transfection experiments, basal StAR promoter activity was unaltered by the mutation in murine Y-1 cells and human H295R cells. In Y-1 cells, forskolin (25 µM, 6 h) significantly increased wild-type promoter activity to 230±33% (P<0.05, n=4). In contrast, forskolin increased mutated promoter activity only to 150±27%, with a significant 35% reduction compared to wild type (P<0.05, n=3). In H295R cells, angiotensin II (AngII; 10 nM) increased wild-type StAR promoter activity to 265±22% (P<0.01, n=3), while mutated StAR promoter activity in response to AngII only reached 180±29% of controls (P<0.01, n=3). Gel mobility shift assays show the formation of two additional complexes with the mutated promoter: one with the transcription repressor DAX-1 and another with a yet unidentified factor, which strongly binds the SF-1 response element. Thus, this novel mutation in the human StAR promoter is critically involved in the regulation of StAR gene expression and is associated with reduced promoter activity, a finding relevant for adrenal steroid response to physiological stimulators.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.